InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,712.69
(
-0.28%
)
US TECH 100
19,522.80
(
0.42%
)
Dow Jones
41,794.60
(
-0.61%
)
Brent Oil
75.32
(
0.27%
)
Bitcoin
68,789.43
(
1.43%
)
Post# of 80490
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

biotech_researcher

Send PM Follow Ignore
Followers 84
Posts 12546
Boards Moderated 0
Alias Born 07/25/2008

biotech_researcher

Re: Whosetosay post# 37077

Saturday, 10/26/2013 1:24:25 PM

Saturday, October 26, 2013 1:24:25 PM

Post# of 80490

At some point we'll be hearing from Dr. Cortes. Not sure if it's good or bad we haven't yet.



2damoon, at this point, Dr. Cortes' data in a front line setting is not very valuable as the patients have not been on the drug very long, and the concerns are the ramp up of CV issues at 24 months. HOWEVER, if MD Anderson continues the trial, it will have a revealing look of the effect of Iclusig on naive patients. If positive, that could be significantly important.
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up